ГоловнаArchive of numbers2019Volume 27, issue 4 (101)Dynamics of Quality of Life Indices in Case of Metabolic Syndrome in Patients with Paranoid Schizophrenia on the Background of Atypical Neuroleptic Agents Application and Improvement of Comorbidity
Title of the article Dynamics of Quality of Life Indices in Case of Metabolic Syndrome in Patients with Paranoid Schizophrenia on the Background of Atypical Neuroleptic Agents Application and Improvement of Comorbidity
Authors Romash Ivan
Vynnyk Mykhailo
In the section DIAGNOSTICS AND THERAPY OF MENTAL AND NARCOLOGICAL DISORDERS
Year 2019 Issue Volume 27, issue 4 (101) Pages 62-67
Type of article Scientific article Index UDK [616.891.8+616-008]-085.214.2 Index BBK -
Abstract The objective of the research was to study the features of quality of life dynamics depending on clinical and psychopathological symptoms in patients with paranoid schizophrenia asso ciated with metabolic syndrome on the background of long-term neuroleptic therapy and to study the eff ectiveness of concomitant corrective therapy. 140 patients with paranoid schizophrenia (F20.0) were examined and divided into three groups. Group I included 40 patients who received haloperidol at an ave rage daily dose of 4.6 ± 1.3 mg/day, Group II consisted of 40 patients who received risperidone (3.7 ± 1.8 mg/day), Group III included 40 patients who received quetiapine (413 ± 116 mg/day). Half of the patients in each of the presented groups continued to receive neuroleptic therapy according to the above mentioned regimen, and the other half of the patients received metformin hydro chloride at a dose of 500 mg/day in addition to the standard therapy. The cont rol group consisted of 20 patients diag nosed with "paranoid schizophrenia, remission", without metabolic syndrome signs, who had not received neuroleptics for the past six months. The Positive and Negative Syndrome Scale (PANSS) and the Medical Outcomes Study 36-Item Short-Form Health Status Questionnaire (SF-36) were used to study the patients’ mental health in detail. In this research, we monitored the impact of comorbidity on quality of life indices in the patients with long-lasting treatment of schizophrenia by neuroleptic agents, and noted that concomitant corrective therapy was appropriate in terms of compliance increase and quality of life indices improvement in the studied category of patients.
Key words paranoid schizophrenia, metabolic syndrome, atypical neuroleptic agents, quality of life
Access to full text version of the article pdf download
Bibliography


1. Opria Ye. V. Osoblyvosti sotsialnoho funktsionuvannia, yakosti zhyttia ta komplaiensu khvorykh na shyzofreniiu z tsukrovym diabetom // Eksperymentalna i klinichna medytsyna. 2018. № 4 (81). S. 45—51.
2. Opria Ye. V., Pustovoit M. M. Osoblyvosti usvidomlennia psykhichnoi ta somatychnoi khvoroby u khvorykh na shyzofreniiu, poiednanu z tsukrovym diabetom // Arkhiv psykhiatrii 2018. T. 24, № 4 (95). S. 197—201.
3. Zubatiuk O. V., Pyliahina H. Ya. Porushennia upravlinnia emotsiiamy i sotsialnoho funktsionuvannia pry psykhozakh z depresyvno-paranoidnoiu symptomatykoiu // Psykhosomatychna medytsyna ta zahalna praktyka. 2018. T. 3, № 4. S. 1/7—7/7. URI: http://lib.inmeds.com.ua:8080/jspui/handle/lib/9000.
4. Yurchenko O. M., Linskyi I. V. Yakist zhyttia u khvorykh na paranoidnu shyzofreniiu ta yii diahnostychne znachennia // Ukrainskyi visnyk psykhonevrolohii. 2017. T. 25, vyp. 2 (91). S. 92—96. 5. Moskalenko V. F., Bulakh I. Ye., Puzanova O. H. Metodolohiia dokazovoi medytsyny : pidruchnyk. K. : «Medytsyna», 2014. 200 s.
6. Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: Data from the CATIE schizophrenia trial sample at baseline / H. A. Nasrallah, J. M. Meyer, D. C. Goff [et al.] // Schizophrenia Research. 2006. Vol. 86, No. 1—3. P. 15—22. DOI: 10.1016/j.schres.2006.06.026.
7. Smashna O. Ye. Vplyv suputnoi somatychnoi patolohii na otsinku yakosti zhyttia patsiientamy, shcho strazhdaiut na paranoidnu formu shyzofrenii // Ukrainskyi visnyk psykhonevrolohii. 2011. T. 19, vyp. 3 (68). S. 70—73.
8. Screening of cardiovascular risk factors in patients with schizophrenia and patients treated with antipsychotic drugs: are we equally exhaustive as with the general population? / Castillo-Sanchez M., Fabregas-Escurriola M., Berge-Baquero D. [et al.] // Clin Exp Hypertens. 2017. 39(5). P. 441—447. DOI: 10.1080/10641963.2016.1267200.
9. Increased Mortality in Schizophrenia Due to Cardiovascular Disease — A Non-Systematic Review of Epidemiology, Possible Causes, and Interventions / Ringen P. A., Engh J. A., Birkenaes A. B. [et al.] // Front Psychiatry. 2014. 5. P. 37. DOI: 10.3389/fpsyt.2014.00137.
10. Pidkorytov V. S., Baibarak N. A. Porushennia sotsialnoho funktsionuvannia u khvorykh na paranoidnu shyzofreniiu z suputnoiu somatonevrolohichnoiu patolohiieiu // ScienceRise: Medical Science. 2017. № 4(12). S. 46—50.
11. Kay S. R., Fiszbein A., Opler L. A. The positive and Negative Syndrome Scale (PANSS) for Schizophrenia // Schizophrenia Bulletin. 1987. 13 (2). Р. 261—276. DOI: 10.1093/schbul/13.2.261.
12. SF-36® Health Survey Manual and Interpretation Guide / Ware J. E., Snow K. K., Kosinski M., Gandek B. Boston, MA : New England Medical Center, The Health Institute, 1993.